Ranbaxy Laboratories now part of Sun Pharma was established in 1961. Throughout its history, Ranbaxy has been committed providing affordable generic alternatives and to the research and development of new medications, this is emphasised by its five state of the art research and development facilities. Since its merger with Sun Pharma in 2015, research and development has remained a core principal in the quest for new and innovative solutions.
Ranbaxy operates one of the largest and most geographically diverse manufacturing networks in the industry. This network allows it to supply generic treatments to over 125 different countries in all parts of the globe, all now accessible through the internet. The significant investment in researching and developing, as well as synthesising reliable treatments, has allowed it to bring down the cost of essential drugs worldwide.
As a market leader, Ranbaxy assures regulatory approval by adhering to medication development methods and stringent quality standards. It performs thorough preclinical and clinical research to demonstrate the safety and efficacy of its medications. Throughout the development process, it closely collaborates with regulatory bodies to ensure adherence to their rules. Transparency is supported and the company's dedication to providing patients with safe and effective pharmaceuticals is upheld by continued drug performance monitoring after approval.
Built on a set of principles that include integrity, excellence, and patient wellbeing, Ranbaxy now Sun Pharma is dedicated to ensuring compliance with regulatory standards at the same time as fostering a culture of transparency. Through innovation and research, they strive for excellence in product development, focusing on high-quality, affordable medications. By actively engaging with patients and healthcare providers, Sun Pharma delivers on its commitment to improving health outcomes and ensuring that patient needs remain at the forefront of its operations.
